A Systems Approach to Targeting Innate Immunity in AD

针对 AD 中先天免疫的系统方法

• 批准号: 10246077
• 负责人: NILUFER ERTEKIN-TANER
• 金额: $ 323.37万
• 依托单位: MAYO CLINIC JACKSONVILLE
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-01 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10246077
• 关键词: Affect; Agonist; Alzheimer' s Disease; Alzheimer' s disease risk; Amyloid; Biological; Biological Models; Brain; Brain region; Cerebellar Cortex; Collaborations; Communities; Data; Data Analyses; Disease; Drug Targeting; Economics; Elderly; Epigenetic Process; Equilibrium; Evaluation; Funding; Future; Generations; Genes; Genetic Transcription; Genetic study; Genotype; Goals; Grant; Immune Targeting; Immune system; Information Systems; Innate Immune System; Knowledge; Mediating; Medical; Medicine; Mining; Modeling; Molecular; Natural Immunity; Nerve Degeneration; Other Genetics; PLCG2 gene; Pathologic; Pathology; Pathway Analysis; Pathway interactions; Patients; Phase; Play; Population; Pre-Clinical Model; Process; Progressive Supranuclear Palsy; Proteome; Recombinant adeno-associated virus (rAAV); Role; Slice; Study models; System; TREM2 gene; Tauopathies; Temporal Lobe; Testing; Therapeutic; Validation; base; clinical efficacy; cohort; comparative; cost; data tools; genome-wide; human data; immune activation; in vivo; innovation; insight; member; mouse model; new therapeutic target; novel; novel therapeutic intervention; open data; pathological aging; research clinical testing; risk variant; tau Proteins; therapeutic evaluation; therapeutic target; transcriptome; transcriptomics; whole genome

Our funded U01 project in the AMP-AD consortium had the overarching aim of identifying therapeutic targets within innate immunity pathways. In the previous funding period, we made significant progress and met all milestones of our U01. We have nominated multiple targets in the immune system, and these targets are at various stages of validation. Nevertheless, key gaps in our understanding impede transformation of the collective AMP-AD knowledge to validated therapeutic targets. Despite identification of numerous perturbed transcriptional networks, some enriched for Alzheimer's disease (AD) risk genes, key tractable targets in these networks are not unequivocally identified and validated. Further, whether the observed transcriptional changes are a simple consequence of disease or actually, play a role in the pathologic cascade has, typically, not been determined. Finally, the direction of molecular changes that is beneficial vs. detrimental has, in most cases of nominated targets, not been established. To overcome these gaps in knowledge, we will i) leverage unique aspects of our existing data and tools along with data and analyses generated by the larger AMP-AD consortia, ii) generate complementary new data, and iii) apply innovative analytic approaches. Notably, our ability to perform comparative analysis of control (no pathology), PathAg, (Pathologic Aging, amyloid+), AD (tau+, amyloid+) and PSP (progressive supranuclear palsy, tau+) enables a framework to identify therapeutic targets that play a role in the transition to different disease stages of AD. Further, comparisons between two brain regions (TCX=affected and CER=largely spared in AD) and between AD and PSP can help distinguish whether the molecular changes identified are likely a cause or consequence of pathology. In this renewal application, we propose to: i) refine and genetically validate therapeutic targets ii) identify molecular mechanisms and targets that mediate disease transition from control to PathAg to AD iii) define the drug target mechanism(s) iv) evaluate select prioritized targets in relevant models, v) continue the collaboration with all AMP-AD partners to promote consortium wide-target validation and vi) share our data openly with the larger scientific community. These studies will include the final phase of modeling studies for more than 20 immune targets identified in the original grant cycle with a goal of making firm go, no-go, decisions on select targets. These studies will enable us to i) provide biologic insight into the mechanism of action of the proposed targets and ii) inform on the direction of change needed for therapeutic benefit. Identification of key targets that drive the transition from control to amyloid positivity, and then to tau pathology and neurodegeneration will enable us to propose alignments of future clinical testing of therapeutics that manipulate these targets in appropriate disease stages-increasing the likelihood to achieve clinical efficacy and avoiding costly testing of an agent in an intent to treat population that is unlikely to benefit.

我们在AMP-AD联盟中资助的U 01项目的首要目标是确定治疗靶点 在先天免疫途径中。在上一个资助期，我们取得了重大进展，并满足了所有 我们U 01的里程碑。我们已经提名了免疫系统中的多个靶点，这些靶点位于 验证的各个阶段。然而，我们认识上的关键差距阻碍了集体经济的转变。 AMP-AD知识与经验证的治疗靶点。尽管鉴定了许多干扰转录 网络，一些富含阿尔茨海默病（AD）风险基因，这些网络中的关键易处理目标是 没有明确的识别和验证。此外，观察到的转录变化是否是一个简单的 疾病的后果或实际上，在病理级联反应中发挥作用，通常尚未确定。 最后，在大多数情况下，有利与有害的分子变化方向 目标，尚未确定。为了克服这些知识差距，我们将i）利用我们的独特方面， 现有的数据和工具沿着由较大的AMP-AD联盟生成的数据和分析，ii）生成 补充新的数据，和iii）应用创新的分析方法。值得注意的是，我们的能力， 对照（无病理）、PathAg（病理老化，淀粉样蛋白+）、AD（tau+，淀粉样蛋白+）和 PSP（进行性核上性麻痹，tau+）使一个框架，以确定发挥作用的治疗靶点 在向AD的不同疾病阶段过渡的过程中。此外，比较两个大脑区域 (TCX=受影响且CER= AD基本上不受影响）以及AD和PSP之间的差异可以帮助区分是否 鉴定的分子变化可能是病理的原因或结果。在此更新申请中，我们 建议：i）完善和遗传验证治疗目标ii）确定分子机制和目标 iii）定义药物靶向机制iv）评估 在相关模式中选择优先目标，v）继续与所有AMP-AD合作伙伴合作， 联盟广泛的目标验证和vi）与更大的科学界公开分享我们的数据。这些 研究将包括对最初确定的20多个免疫靶点进行建模研究的最后阶段。 赠款周期的目标是使公司去，不去，选择目标的决定。这些研究将使我们能够i） 提供对拟议目标的作用机制的生物学见解，以及ii）告知 为了治疗益处而需要改变。确定推动从控制向控制过渡的关键目标 淀粉样蛋白阳性，然后到tau病理学和神经变性将使我们能够提出对齐， 在适当的疾病阶段操纵这些靶点的治疗剂的未来临床试验-增加 实现临床疗效的可能性，并避免在意图治疗人群中进行昂贵的药剂测试， 不太可能受益。